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IMPORTANCE Existing cerebrospinal fluid (CSF) or imaging (tau positron emission
tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers
based on standard blood test results would be useful in research, drug development, and
clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a
blood-based biomarker for neurodegeneration in dementias.
OBJECTIVE To test whether plasma NFL concentrations are increased in AD and associated
with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration.
DESIGN, SETTING, AND PARTICIPANTS In this prospective case-control study, an ultrasensitive
assay was used tomeasure plasma NFL concentration in 193 cognitively healthy controls, 197
patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the
Alzheimer’s Disease Neuroimaging Initiative. The study dates were September 7, 2005, to
February 13, 2012. The plasma NFL analysis was performed in September 2016.
MAIN OUTCOMES ANDMEASURES Associations were tested between plasmaNFL and
diagnosis, Aβ pathologic features, CSF biomarkers of neuronal injury, cognition, brain
structure, andmetabolism.
RESULTS Among 193 cognitively healthy controls, 197 patients with mild cognitive
impairment, and 180 patients with ADwith dementia, plasma NFL correlated with CSF NFL
(Spearman ρ = 0.59, P < .001). Plasma NFL was increased in patients with MCI (mean, 42.8
ng/L) and patients with AD dementia (mean, 51.0 ng/L) compared with controls (mean, 34.7
ng/L) (P < .001) and had high diagnostic accuracy for patients with ADwith dementia vs
controls (area under the receiver operating characteristic curve, 0.87, which is comparable to
established CSF biomarkers). Plasma NFL was particularly high in patients with MCI and
patients with AD dementia with Aβ pathologic features. High plasma NFL correlated with
poor cognition and AD-related atrophy (at baseline and longitudinally) and with brain
hypometabolism (longitudinally).
CONCLUSIONS AND RELEVANCE Plasma NFL is associated with AD diagnosis andwith
cognitive, biochemical, and imaging hallmarks of the disease. This finding implies a potential
usefulness for plasma NFL as a noninvasive biomarker in AD.
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A lzheimer disease (AD) is a neurodegenerative diseasethat is characterized by brain accumulation of β-amy-loid (Aβ)andtau,progressiveatrophy,andcognitivede-
cline. Biomarkers that capture biological processes in AD are
increasingly used to support the diagnosis of AD in research,
drug development, and clinical practice.1 The most well-
established AD biomarkers include structural magnetic reso-
nance imaging (MRI); cerebrospinal fluid (CSF) biomarkers of
Aβ, tau, and neuronal injury; and positron emission tomo-
graphic imagingofAβ,tau,andbrainmetabolism.2-4Useofthese
biomarkers is hamperedbyahighdegreeof invasiveness, high
costs, or limited availability.5 Blood-based biomarkers for AD
may allow for efficient monitoring of disease processes in AD
and could be used as a screening tool in primary care. One po-
tential blood-based biomarker for AD is the neuronal injury
marker neurofilament light (NFL)6 because patients with AD
have increasedCSFconcentrationsofNFL.7Results fromsome
studies8,9 suggest thatpatientswithADhave increasedplasma
NFL concentrations. However, those studies were performed
using standard immunoassay techniques with suboptimal
analytical sensitivity to accurately quantify low abundant
brain-specific proteins in blood samples.10 For this reason,
our group has recently transferred the CSF NFL assay to an
ultrasensitive single-molecule array (Simoa; Quanterix Cor-
poration) platform, which provides an analytical sensitivity
of 0.6 pg/mL compared with 78.0 pg/mL for the correspond-
ing enzyme-linked immunosorbent assay (ELISA).10 Plasma
NFL concentrations can be measured in all samples using
the ultrasensitive single-molecule array and correlate closely
with the corresponding CSF concentrations.11,12 Herein, we
test this novel plasma NFL assay in patients with AD for
the first time, to our knowledge. We studied cognitively
healthy control individuals, patients with mild cognitive
impairment (MCI) (MCI group), and patients with AD demen-
tia (AD group) in a large prospective study. We tested the
hypotheses that the plasma NFL concentration is increased
in AD and that it correlates with impaired cognition, neuro-
imaging abnormalities, and CSF biomarkers of AD pathologic
features.
Methods
ADNI Study Design
Data were obtained from the Alzheimer’s Disease Neuroim-
aging Initiative (ADNI)database (http://adni.loni.usc.edu).The
ADNI was launched in 2003 as a public-private partnership,
ledbyprincipal investigatorMichaelW.Weiner,MD (themost
recent information on the ADNI is available at http://www
.adni-info.org).TheADNIparticipantshavebeenrecruitedfrom
more than 50 sites across the United States and Canada. For
thepresent study,weuseddata accessed from theLaboratory
of Neuro Imaging (University of Southern California) ADNI
databaseonOctober6, 2016.The studydata andsampleswere
collected from September 7, 2005, to February 13, 2012.
Regional ethical committees of all participating institutions
approved the ADNI. All study participants provided written
informed consent.
ADNI Participants
OurADNI cohort consisted of all cognitively healthy controls,
patientswithMCI, and patientswith ADdementiawith avail-
able baseline plasma NFL samples from the ADNI-1. Inclu-
sionandexclusioncriteriaweredescribed indetailpreviously.13
Briefly, all ADNI-1 participants were aged 55 to 90 years, had
completed at least 6 years of education, were fluent in Span-
ish or English, and had no substantial neurological disease
other than AD. Controls had Mini-Mental State Examination
(MMSE) scores of 24 or higher, where lower scores indicate
more impairment and higher scores less impairment (range,
0-30), and a Clinical Dementia Rating (CDR) score of 0,where
lower scores indicate less impairment and higher scores
more impairment (range, 0-3). Patients with MCI had MMSE
scores of 24 or higher, objective memory loss tested by
delayed recall of the Wechsler Memory Scale (WMS) logical
memory II (>1 SD below the normal mean), a CDR score of
0.5, preserved activities of daily living, and absence of
dementia. Patients with AD dementia fulfilled the National
Institute of Neurological Communicative Disorders and
Stroke–Alzheimer Disease and Related Disorders Association
criteria for probable AD,14 had MMSE scores of 20 to 26, and
had CDR scores of 0.5 to 1.0.
PlasmaNFL
Plasma NFL concentrations were measured using an NFL kit
(NF-light; UmanDiagnostics), transferred onto theultrasensi-
tive single-molecule array platform using a home brew kit
(SimoaHomebrewAssayDevelopment Kit; Quanterix Corpo-
ration), as previously described.15 In the 14 analytical runs
needed to complete the study, the relative error of the back-
calculated concentrations was below 20% for all calibrators,
run in triplicate, resulting in lower limits of quantifications of
2.2 ng/L and upper limits of quantification of 1620 ng/L. All
samples measured within the range spanned by the limits of
quantifications, and for the low-concentration quality con-
trol sample (14 ng/L), the intra-assay coefficient of variation
was 11.0%and the interassaycoefficientofvariationwas 11.1%.
For the high-concentration quality control sample (137 ng/L),
the corresponding coefficients of variation were 8.8% and
9.6%, respectively.Themeasurementswereperformed inSep-
tember 2016 by a board-certified laboratory technician using
a single batch of reagents.
Key Points
Question What is the importance of plasma neurofilament light in
Alzheimer disease?
Findings In this case-control study of 193 cognitively healthy
controls, 197 patients with mild cognitive impairment, and 180
patients with Alzheimer disease dementia, plasma neurofilament
light was associated with Alzheimer disease and correlated with
future progression of cognitive decline, brain atrophy, and brain
hypometabolism.
Meaning Plasma neurofilament light may be a promising
noninvasive biomarker for Alzheimer disease.
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CSFMeasurements
Cerebrospinal fluid was sampled by lumbar puncture from a
subset of the participants, with CSF Aβ42, CSF total tau
(t-tau), andCSFphosphorylated tau (p-tau)measuredusing a
multiplex platform (xMAP; Luminex Corporation) with a kit
(INNO-BIAAlzBio3; FujirebioEurope). Participantswere clas-
sified as Aβ positive or Aβ negative using a previously estab-
lished cutoff (CSFAβ42 < 192ng/L).16We excluded8patients
with AD dementia whowere Aβ negative and therefore likely
to be misdiagnosed. The CSF NFL concentrations were mea-
sured using a commercial ELISA (NF-light; UmanDiagnos-
tics) and have been reported previoushy.7 In total, we in-
cludedCSFdata from 112 controls, 189patientswithMCI, and
90 patients with AD dementia.
Cognition
Cognitionwas assessed byMMSE, Alzheimer Disease Assess-
ment Scale–cognitive subscale (ADAS-Cog 11), delayed recall
of theWMS logicalmemory II, Trail-Making test part B (TMT-
B), and Wechsler Adult Intelligence Scale–Revised (WAIS-R)
digit symbol substitution test. All tests were administered at
baseline and at 6, 12, 18, 24, 36, and48months, except for de-
layed recall of theWMS logical memory II, which was not as-
sessed at 18 months.
Neuroimaging
Structural brain imageswereacquiredusing 1.5-TMRI imaging
systemswithT1-weightedMRI scansusing a sagittal volumet-
ric magnetization-prepared rapid acquisition gradient echo
sequence (at baseline and at 6, 12, 18, 24, 36, and 48months).
A software program (FreeSurfer; https://surfer.nmr.mgh
.harvard.edu/) was used for quantification of cortical thick-
ness and subcortical volumes.17 We used volumetric data for
hippocampal volume and lateral ventricles (averaged be-
tween right and left sides). We used the mean cortical thick-
ness for a set of regions defined apriori basedonwork by Jack
et al18 to represent AD cortex (including entorhinal, inferior
temporal, middle temporal, and fusiform cortex).
Whitematter hyperintensities (WMHs)werequantified at
baseline and at 6, 12, 18, 24, 36, and 48 months using a fully
automatedprotocol.19Positronemissiontomographywith18F-
fluorodeoxyglucose imagedatawere acquired at baseline and
at 6, 12, 18, 24, 36, and 48months.20We createdmean counts
of the lateral and medial frontal, anterior, and posterior cin-
gulate regions, as well as lateral parietal and lateral temporal
regions.
Statistical Analysis
We tested associations between plasma NFL and demo-
graphic factorsusingtheKruskal-Wallis testandSpearmanrank
correlation.Wetestedassociationsbetweenbiochemicalmark-
ers and between plasma NFL and diagnosis using linear re-
gressionmodels.Wecalculateddiagnosticaccuraciesusingarea
under the receiver operating characteristic curve (AUROC)
analysiswith 10-fold cross-validated logistic regressionmod-
els. We tested associations between plasma NFL concentra-
tionsand longitudinal cognition,brainstructure, andbrainme-
tabolismusing linearmixed-effectsmodels.Thesemodelshad
randomintercepts andslopes for timeandanunstructuredco-
variance matrix for the random effects and included the in-
teraction between (continuous) time and plasma NFL as pre-
dictor. All outcome variables in linear mixed-effects models
were standardized to z scores to facilitate comparisons be-
tweenmodalities. Therefore, β coefficients refer to standard-
ized effects (β = 1 implies that an increase of 1 ng/L in plasma
NFL was associated with a 1-SD increase in the dependent
variable).
All tests were 2-sided. Statistical significance was set at
P < .05. All regression analyses were corrected for age, sex,
educational level, diagnosis, and APOE ε4 genotype, as well
as intracranial volume forhippocampusandventricles.All sta-
tistical analyseswereperformedusing a softwareprogram (R,
version 3.2.3; The R Foundation).
Results
Table 1 lists demographics for the study population. In the
whole cohort, plasma NFL correlated with age (Spearman
ρ = 0.35, P < .001) but not with sex (median, 36.2 ng/L for
men vs 37.4 ng/L for women; P = .98), educational level
(ρ = −0.03, P = .52), or APOE ε4 genotype (37.7 ng/L in carri-
ers vs 35.6 ng/L in noncarriers, P = .19). These results were
similar within diagnostic groups, except that plasma NFL
concentrations were higher in APOE ε4 carriers in the MCI
group (35.9 ng/L in carriers vs 39.3 ng/L in noncarriers,
Table 1. Demographics for the Study Populationa
Variable
Controls
(n = 193)
MCI
(n = 197)
AD Dementia
(n = 180) P Value
Age, mean (SD), y 75.9 (4.9) 74.7 (7.5) 75.3 (7.3) .58
Female, No. (%) 87 (45.1) 65 (33.0) 86 (47.8) .007
Educational level, mean (SD), y 16.0 (2.9) 15.8 (3.0) 14.7 (3.1) <.001
APOE ε4 genotype carriers, No. (%) 50 (25.9) 103 (52.3) 123 (68.3) <.001
Plasma NFL, mean (SD), ng/L 34.7 (21.4) 42.8 (29.0) 51.0 (26.9) <.001
MMSE score, mean (SD) 29.1 (1.0) 26.9 (1.8) 23.2 (2.1) <.001
CSF Aβ42, mean (SD), ng/L 207 (52) 165 (52) 134 (23) <.001
Aβ+, No./total No. (%) 41/112 (36.6) 138/189 (73.0) 90/90 (100) <.001
CSF t-tau, mean (SD), ng/L 68 (29) 102 (60) 126 (56) <.001
CSF p-tau, mean (SD), ng/L 25 (15) 36 (19) 44 (20) <.001
Abbreviations: Aβ, β-amyloid;
AD, Alzheimer disease dementia;
CSF, cerebrospinal fluid;
MCI, mild cognitive impairment;
MMSE, Mini-Mental State
Examination; NFL, neurofilament
light; p-tau, phosphorylated tau;
t-tau, total tau.
a P values are from the Kruskal-Wallis
test or Fisher exact test. β-Amyloid
positivity was defined as CSF Aβ42
less than 192 ng/L.
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P = .049) and in the AD dementia group (41.6 ng/L in carri-
ers vs 51.5 ng/L in noncarriers, P = .03).
PlasmaNFL andOther Biochemical Markers
in CSF and Plasma
PlasmaNFLcorrelatedwithhighCSFNFL (Spearmanρ = 0.59,
P < .001) (Figure 1) andwith lowCSFAβ42,highCSFt-tau,high
CSF p-tau, and high plasma tau (Table 2). The strongest cor-
relationswere seenwith CSFNFL,whichwere also present in
all diagnostic groups. Plasma NFL also correlated with CSF
Aβ42 and CSF t-tau in the MCI group, as well as with plasma
tau concentrations in all diagnostic groups.
PlasmaNFL in Different Diagnostic Groups
Plasma NFL concentrations were higher in the AD group
compared with controls and the MCI group, as well as in the
MCI group compared with controls (Figure 2A). Plasma NFL
differentiated between the AD dementia group and controls,
with an AUROC of 0.87 (Figure 2B). By comparison, the
AUROCs were 0.87 to 0.90 for CSF NFL, CSF Aβ42, CSF t-tau,
and CSF p-tau and 0.78 for plasma tau. These AUROCs were
corrected for age, sex, educational level, and APOE ε4 geno-
type. When only correcting for age, sex, and educational
level, the AUROCs were reduced to 0.79 for plasma NFL, 0.81
for CSF NFL, 0.85 for CSF t-tau, 0.81 for CSF p-tau, and 0.64
for plasma tau.
PlasmaNFL and Aβ Pathologic Features
WecomparedplasmaNFLbetweenAβ-negative controls, Aβ-
positive controls, Aβ-negative patientswithMCI, Aβ-positive
patientswithMCI, and (Aβ-positive) patientswithADdemen-
tia (Figure2C).TheADdementiagrouphadhigherplasmaNFL
thanAβ-negative controls (mean, 48.8 vs 33.9ng/L;P < .001),
Aβ-positive controls (mean, 30.9 ng/L;P < .001), Aβ-negative
MCI (mean, 38.1 ng/L; P < .001), and Aβ-positive MCI (mean,
44.5 ng/L;P = .05). Therewere no statistically significant dif-
ferencesbetweenAβ-negativeandAβ-positivecontrolsandAβ-
negative patients with MCI.
PlasmaNFL and Progressive vs StableMCI
Among the MCI group, 109 converted to AD dementia dur-
ing follow-up, and 65 remained stable after at least 2 years’
follow-up. Twenty-three patients in the MCI group did not
convert to AD dementia during follow-up but were observed
for less than 2 years and were not included in the stable
group. There was no difference in plasma NFL between
Aβ-positive patients with progressive MCI and Aβ-positive
patients with stable MCI, but both of these groups had
higher plasma NFL than Aβ-negative patients with progres-
sive MCI and Aβ-negative patients with stable MCI
(Figure 2D).
PlasmaNFL and Cognition and Neuroimaging
Associations between plasma NFL and longitudinal cogni-
tive and imaging measures are shown in Figure 3 (coeffi-
cients and P values are listed in the eTable in the Supple-
ment). At baseline, high plasma NFL levels were associated
with worse MMSE, ADAS-COG 11, and TMT-B scores and with
larger ventricular volume, smaller hippocampal volume, and
thinner cortices in the AD cortex region. Over time, high
plasma NFL levels were associated with an accelerated
decline in all measures, except for WMHs. The strongest
influences were seen in MMSE (β = −0.073, P < .001 baseline
and β = −0.116, P < .001 longitudinally) and ADAS-COG11
scores (β = 0.101, P < .001 baseline and β = 0.106, P < .001
longitudinally) for the cognitive measures and in AD
Figure 1. PlasmaNeurofilament Light (NFL) and Cerebrospinal Fluid
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Fit lines are shown for individual diagnostic groups. The Spearman ρ and P
values are for Spearman rank correlation in the whole cohort. Table 2 lists
correlation data adjusted for covariates. AD indicates Alzheimer disease; MCI,
mild cognitive impairment.
Table 2. Correlations Between PlasmaNFL andOther Biochemical Markersa
Biomarker All Participants Controls MCI AD Dementia
β Coefficient P Value β Coefficient P Value β Coefficient P Value β Coefficient P Value
CSF NFL 0.480 <.001 0.371 <.001 0.615 <.001 0.242 .046
CSF Aβ42 −0.144 .01 0.002 .99 −0.243 <.001 −0.017 .87
CSF t-tau 0.125 .01 0.123 .21 0.170 .01 0.033 .76
CSF p-tau 0.105 .03 0.068 .49 0.113 .10 0.112 .31
Plasma tau 0.178 <.001 0.238 <.001 0.138 .03 0.188 .008
Abbreviations: AD, Alzheimer disease; CSF, cerebrospinal fluid; MCI, mild
cognitive impairment; NFL, neurofilament light; p-tau, phosphorylated tau;
t-tau, total tau.
a Data are β coefficients (with P values) from linear regressionmodels for
correlations between plasma NFL and other biomarkers (all standardized
to z scores), adjusted for age, sex, educational level, APOE ε4 genotype, and
diagnosis. Models were tested in the whole cohort and in individual diagnostic
groups.
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cortex (β = −0.162, P < .001 baseline and β = −0.049,
P < .001 longitudinally) for the imaging measures (details are
provided in the eTable in the Supplement).
We also tested whether the influence of plasma NFL
differed between diagnostic groups. Statistically significant
interactions were found at baseline for the MCI group
and MMSE score (β = −0.107, P = .008), ADAS-COG 11 score
(β = 0.150, P = .003), delayed recall of the WMS logical
memory II (β = −0.167, P < .001), TMT-B score (β = 0.283,
P < .001), WAIS-R digit symbol substitution test score
(β = −0.253, P = .002), and AD cortex (β = −0.282, P < .001),
as well as for the AD group and MMSE score (β = −0.133,
P = .002), ADAS-COG 11 score (β = 0.171, P = .001), delayed
recall of the WMS logical memory II (β = −0.117, P = .01), and
AD cortex (β = −0.178, P = .04). These results indicate that
plasma NFL was more strongly correlated with the out-
comes in the MCI group and the AD dementia group than in
controls at baseline. Longitudinally, the only statistically
significant interaction was for the MCI group and MMSE
score (β = −0.107, P = .003), demonstrating that plasma NFL
Figure 2. PlasmaNeurofilament Light (NFL) by Diagnosis and Aβ
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levels were more strongly correlated with longitudinal
MMSE scores in the MCI group than in controls.
Discussion
Wepresent the first large study, to our knowledge, on plasma
NFL inADdementia. Themain findingswere that plasmaNFL
(1) correlatedwithCSFNFL independent of diagnosis, (2)was
increased in the AD dementia group and in Aβ-positive pa-
tients withMCI, (3) had diagnostic accuracy for AD dementia
in the same range as established CSF biomarkers, and (4) was
associated with cognitive deficits and neuroimaging hall-
marks ofADat baseline andduring follow-up. Together, these
findings support that plasmaNFL is apromisingbiomarker for
neuronal injury in AD, which may have potential for progno-
sis andmonitoringofdiseaseprogression.Thisbiomarkermay
be useful in clinical studies, in drug development, and ulti-
mately in clinical practice.However, increasedplasmaNFLxc
concentrations are also found in several other neurodegen-
erativedisorders, suchasprogressive supranuclearpalsy, fron-
totemporal dementia, and human immunodeficiency virus
with brain engagement,11,12,15 meaning that it lacks disease
specificity for AD. Therefore, we do not envision plasmaNFL
as a tool todifferentiateAD fromotherneurodegenerativedis-
eases.Rather, itmaybevaluableasageneralbiomarker forneu-
rodegeneration.
Plasma NFL correlated with CSF NFL levels in the whole
cohort and in diagnostic groups. Although these correlations
were statistically significant, particularly in the whole co-
hort, the correlationcoefficientswere slightly lower thanwhat
was seen in previous studies of plasma or serum NFL levels,
which included individuals with human immunodeficiency
virus,11 progressive supranuclear palsy,12 other neurological
diseases,10 and minor neurosurgical trauma.21 Hypotheti-
cally, it is possible that a greater variability inplasmaNFLcon-
centrations in AD compared with previously tested diseases
could have influenced the correlations between plasma NFL
and CSFNFL. PlasmaNFL also correlatedwith other CSF bio-
markers in the whole cohort, but those correlations were of-
tennot statistically significantwithin diagnostic groups, sug-
gesting that theywere confounded by diagnosis. This finding
probably reflects that several different pathologic conditions
are present in AD (eg, Aβ pathologic features, tau pathologic
findings, and degeneration of different types of axons) and
drivedifferentbiomarker responses,whichwill beweakly cor-
relatedoverall. InMCI, aheterogeneouscondition,highplasma
NFL levles correlated with low CSF Aβ42 and high CSF t-tau,
Figure 3. Associations Between PlasmaNeurofilament Light and Cognitive and NeuroimagingMeasures
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Data from linear mixed-effects models adjusted for age, sex, educational level,
APOE ε4 genotype, and diagnosis, as well as intracranial volume for the
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ADAS-COG 11 indicates Alzheimer Disease Assessment Scale–cognitive subscale;
AD cortex, Alzheimer disease cortex; Digit symbol, Wechsler Adult Intelligence
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Logical memory DR, delayed recall of theWechsler Memory Scale logical
memory II; MMSE, Mini-Mental State Examination; Q, quartile;
TMT-B, Trail-Making test part B; andWMHs, white matter hyperintensities.
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and this correlation supports the use of plasma NFL as a
biomarker sensitive toAD-relatedbiological changes inprodro-
malAD. PlasmaNFLalso correlatedwithplasma tau in all diag-
nosticbagroups.Althoughplasmatauappearstobeaweakerbio-
marker for neuronal injury thanplasmaNFL,22 thesemeasures
maypartly reflect the sameprocess (eg, axonal degeneration).
TheADdementiagrouphadhigherplasmaNFL levels than
theMCI group, and theMCI groupand theADdementia group
had higher plasma NFL levels than the controls. Although
plasma NFL overlaps between the diagnostic groups, the ac-
curacy of plasma NFL for AD dementia vs controls is close to
established CSF AD biomarkers and much higher than for
plasma tau (AUROC, 0.87 vs 0.78 when adjusted for demo-
graphics and APOE ε4; AUROC, 0.79 vs 0.64 when adjusted
only for demographics). To our knowledge, this study repre-
sents the first time that a peripheral, noninvasive biomarker
for neuronal injury has shown diagnostic accuracy for AD
dementia comparablewith established biomarkers in a large-
scale multicenter cohort.
In the MCI group, plasma NFL levels were increased pri-
marily in Aβ-positive patients with MCI (ie, prodromal AD).
Plasma NFL concentration did not differ between clinically
stable andprogressiveAβ-positive patientswithMCI. This re-
sultmayhavebeen influencedbytheshort follow-uptimeused
to define stable MCI (2 years), which may be too abbreviated
to verify the benignnature of the so-called stable condition.23
The finding that plasma NFL concentrations were increased
already in prodromal AD is promising because it may render
plasmaNFLmoreuseful indrugdevelopment,which is largely
focused on this early stage of AD,1 as well as in clinical prac-
ticebecausepatientswithMCI increasinglyseekmedicalevalu-
ation. PlasmaNFLdidnot differ betweenAβ-positive andAβ-
negativecontrols, suggesting thatanyneuronal injury thatmay
haveoccurred inAβ-positive controls (ie, preclinicalAD) is be-
low the detection limit for plasma NFL. This result is well in
line with the theory that preclinical AD is devoid of substan-
tial neuronal injury.24,25
The final major finding was that plasma NFL was associ-
ated with several cognitive and imaging AD hallmarks at
baseline and when those measures were analyzed over time.
Specifically, plasma NFL was associated with general cogni-
tion (MMSEscore andADAS-COG11 score) andexecutive func-
tion (TMT-B score) at baseline and with decline in all tested
cognitivemeasures over time. The somewhat stronger corre-
lations with timed tests, including TMT-B and WAIS-R digit
symbol substitution test, comparedwith thememory testmay
suggest that plasma NFL primarily reflects damage to larger
myelinated axonal processes of neurons. For imaging mea-
sures, associations were seen with lateral ventricles, hippo-
campal volume, andAD cortex thickness at baseline and over
time, aswell as with hypometabolism over time. The correla-
tions were strongest in the MCI group and the AD dementia
group but were statistically significant in the whole cohort
when adjusting for diagnosis.
Limitations
This study is limited by the lack of patientswith neurodegen-
erative diseases other than AD, which prevented our testing
fordisease specificity of plasmaNFL.Another limitation is the
restricted sample in the ADNI, such that patients with sub-
stantial vascular burden were excluded. This exclusion may
have made it difficult to detect subtle associations between
plasmaNFLandwhitematter pathologic findings andmayex-
plain the surprising finding that plasmaNFLdid not correlate
with WMHs, despite that CSF NFL has been considered a
markerofwhitematterpathologic features,26 including inAD.7
Future studies should test plasma NFL in a more unselected
groupofpatientswithADandmayalso exploredifferentprox-
ies forwhitematter injury. A larger age span should also be in-
cluded in future work because it is possible that vascular co-
morbidities may change with age and alter the diagnostic
accuracy of plasma NFL for patients with AD vs controls and
other diseases.
Allmain resultswere in theexpecteddirections,without il-
logical data. Themain findings that plasmaNFL concentration
wasincreasedintheADdementiagroupandcorrelatedwithCSF
NFL, imaging, and cognitive hallmarks of AD were all statisti-
cally significant. We believe that the consistency of these data
makes it unlikely that theywere falsely positive. Therefore,we
reported P values uncorrected formultiple comparisons.
Conclusions
We found that plasma NFL concentration is increased in AD,
even in prodromal disease, and that it correlates with impor-
tant disease hallmarks, measured by cognitive tests, neuro-
imaging, and CSF biomarkers. The fact that plasma NFL
concentration is also elevated in other neurological
diseases11,12,15 and that NFLmay be released from neurons in
Aβ-dependentandAβ-independentpathologicconditions27ar-
gues against the use of plasma NFL for differential diagnosis
ofADvsotherdementias.However,plasmaNFLmaybeavalu-
ablenoninvasive tool toassessneurodegenerationand to iden-
tify individuals at risk for future cognitive decline and brain
atrophy. Therefore, plasmaNFL is a promisingperipheral bio-
marker for neurodegeneration, including in AD. In a clinical
trial scenario, it is possible that plasma NFLmay be used (to-
getherwithdemographics andAPOE ε4genotypedata) topre-
dict longitudinal disease progression. Future studieswith re-
peated samples should test plasma NFL as a longitudinal
noninvasive proxy for neurodegeneration.
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